Day: June 7, 2020

Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China

Written by Customer Service on . Posted in Public Companies.

First healthy volunteer has been dosed in a Phase I study of JS016, the first SARS-CoV-2 neutralizing antibody to enter the clinical stage in ChinaJunshi and Lilly will co-develop JS016 globallyJS016 is a recombinant fully human monoclonal neutralizing antibody that blocks the binding of the SARS-CoV-2 virus to the host cell surface receptor ACE2SHANGHAI, China, June 07, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that the first healthy volunteer has been dosed in the Phase I clinical study of JS016 at Huashan Hospital Affiliated to Fudan University in China. JS016 is the first SARS-CoV-2 neutralizing antibody to enter clinical trials in China. Junshi and Eli Lilly...

Continue reading

SouthGobi Announces Settlement Agreement

Written by Customer Service on . Posted in Public Companies.

VANCOUVER, British Columbia, June 07, 2020 (GLOBE NEWSWIRE) — SouthGobi Resources Ltd. (TSX: SGQ, HK: 1878) (“SouthGobi” or the “Company”) announces that SGS and First Concept entered into a settlement agreement on June 7, 2020 (the “Settlement Agreement”).Reference is made to the announcement of the Company dated June 2, 2020 in relation to the enforcement on Arbitration Award (“Announcement”). Unless the context otherwise requires, capitalized terms used herein shall have the same meanings as those defined in the Announcement. Pursuant to the Settlement Agreement, SGS shall pay to First Concept a settlement sum in full and final settlement of any and all claims which First Concept may have against SGS in relation to Arbitration Award, the subject matter of the Arbitration Award including any claims for interests and costs and...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.